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Abstract
Background: Fish currently supplies only 40% of the eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
needed to allow all individuals globally to meet the minimum intake recommendation of 500 mg/d. Therefore, alternative
sustainable sources are needed.
Objective: The main objective was to investigate the ability of genetically engineered Camelina sativa (20% EPA) oil (CO)
to enrich tissue EPA and DHA relative to an EPA-rich fish oil (FO) in mammals.
Methods: Six-week-old male C57BL/6J mice were fed for 10 wk either a palm oil–containing control (C) diet or diets
supplemented with EPA-CO or FO, with the C, low-EPA CO (COL), high-EPA CO (COH), low-EPA FO (FOL), and high-EPA
FO (FOH) diets providing 0, 0.4, 3.4, 0.3, and 2.9 g EPA/kg diet, respectively½AQ3 . Liver, muscle, and brain were collected for
fatty acid analysis, and blood glucose and serum lipids were quantified. The expression of selected hepatic genes involved
in EPA and DHA biosynthesis and in modulating their cellular impact was determined.
Results: The oilswerewell tolerated,with significantly greaterweight gain in theCOHand FOHgroups relative to theCgroup (P<
0.001). Significantly lower (36–38%) blood glucose concentrations were evident in the FOH and COHmice relative to Cmice (P <
0.01). EPA concentrationswere higher in all EPA groups relative to theC group (P<0.001), with concentrations of 0.0, 0.4, 2.9, 0.2,
and 3.6 g/100 g liver total lipids in the C, COL, COH, FOL, and FOH groups, respectively. Comparable dose-independent
enrichments of liver DHAwere observed after COandFO (P<0.001). Relative to theCgroup, lower fatty acid desaturase 1 (Fads1)
expression (P < 0.005) was observed in the COH and FOH groups, and higher fatty acid desaturase 2 (Fads2), peroxisome
proliferator–activated receptor a (Ppara), and peroxisome proliferator–activated receptor g (Pparg) (P< 0.005) were induced by CO.
No impact of treatment on liver X receptor a (Lxra) and sterol regulatory element-binding protein 1c (Srebp1c) was evident.
Conclusions: Oil from transgenic Camelina is a bioavailable source of EPA in mice. These data provide support for the
future assessment of this oil in a human feeding trial. J Nutr 2016;146:1–9.
Keywords: n–3 PUFA, EPA, DHA, Camelina oil, fish oil, sustainability, desaturation, Fads, transgenic, TG sn-2
Introduction
Although randomized controlled trials have not been completely
consistent, a large body of human prospective cohort evidence,
as well as animal feeding studies, have shown the beneficial
impact of the n–3 (v -3) long-chain (LC)9 PUFAs EPA (20:5n–3)
and DHA (22:6n–3) on fetal development and cardiovascular
and cognitive health (1–4). In humans, EPA, and to a lesser
extent DHA, can be synthesized de novo from their precursor
essential FA, a-linolenic acid (ALA; 18:3n–3), which is partic-
ularly rich in several seed oils. However, this bioconversion, in
3 Supplemental Tables 1–5 are available from the ‘‘Online Supporting Material’’
link in the online posting of the article and from the same link in the online table of
contents at http://jn.nutrition.org.
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which elongases (ELOVLs; encoded by ELOVL2 and
ELOVL5) and D5 and D6 desaturases [encoded by FA
desaturases (FADS) 1 (FADS1) and 2 (FADS2)] are key
metabolizing enzymes (5–7), is inefficient (8, 9). Therefore,
based largely on their cardiovascular benefits, international and
national health organizations and societies such as the Interna-
tional Society for the Study of Fatty Acids and Lipids (10), the
UK Scientific Advisory Committee in Nutrition (11), and the
American Heart Association (12) recommend a minimum
dietary intake of 500 mg preformed EPA+DHA/d (achieved
through the consumption of 1 to 2 portions of oily fish per
week), increasing to 1 g or 2–4 g/d for the secondary preven-
tion of cardiovascular diseases or as a TG-lowering therapy,
respectively.
It has been estimated that, globally, ;1.3 million metric tons
of EPA plus DHA per annum are needed to allow all individuals
to have a minimum intake of 500 mg/d. Current sources, which
are almost exclusively derived from fish, provide only 40% of
this (13) [of which >75% is used in aquaculture (14)], leaving a
large deficit between supply and need. Zooplankton and
microalgae have been investigated (15); however, the availability
of EPA and DHA via these sources presents substantial½AQ4 techno-
logical and cost challenges, which are generally limiting their
use. Alternatively, seed oils rich in stearidonic acid (SDA; 18:4n–
3), an intermediate in the synthesis of EPA from ALA, have also
been considered as a possible alternative to fish oil (FO).
Supplementation with a genetically engineered soybean oil to
contain SDA resulted in increased EPA, but not DHA, concen-
trations in human plasma and erythrocytes (16, 17). In aqua-
culture, the partial replacement of FO with either SDA-soybean
oil or Echium oil (naturally rich in SDA) was shown to have
ambiguous effects on growth and performance and did not
enhance tissue n–3 LC-PUFA concentrations, although higher
tissue SDA was evident (which may ultimately improve human
EPA status) (18–21). Therefore, overall, SDA-rich oils have not
emerged as an adequate replacement for FO.
Due to the scalability of agriculture-based sources, metabolic
engineering of oilseed crops (which are naturally devoid of EPA
and DHA) to accumulate these FAs is emerging as one of the
most practical solutions to n–3 LC-PUFA supply (22–24).
Camelina sativa is a Brassicaceae½AQ5 crop that naturally has a
high content (45%) of the precursor ALA. By using transgenic
technology and the introduction of heterologous genes (from
microalgae) of the biosynthetic pathway and their regulators
into Camelina, this oilseed has been genetically engineered to
produce oils containing up to 30% EPA or EPA+DHA (25–27).
One of these transgenic seed oils, containing 20% of total FAs as
EPA, was recently used as a replacement for FO in the feeds of
Atlantic salmon (Salmo salar), showing comparable tissue EPA
enrichment to FO (28). The impact on EPA and DHA status
upon direct feeding to humans is currently unknown for this oil.
The aim of the present study was to compare, for the first
time to our knowledge½AQ6 , how equal doses of EPA provided as
EPA-enriched Camelina oil (CO) or EPA-rich concentrated FO
affect tissue FA status in mammals (C57BL/6J mice). Because the
position at which PUFAs are complexed on the glycerol
backbone of TGs (sn1,3) has been shown to affect their
bioavailability and bioefficacy (29, 30), regiospecific analysis
of the CO and FO was performed. Gene expressions of the Elovl
and Fads genes along with transcription factors that modulate
the cellular effects of EPA and DHA, namely peroxisome
proliferator–activated receptor (Ppar) a (Ppara) and Pparg,
sterol regulatory element-binding protein 1c (Srebp1c), and liver
X receptor a ½AQ7(Lxra) (31), were also investigated.
Methods
Animals and design. Experimental procedures and protocols used in
this study were reviewed and approved by the Animal Welfare and
Ethical Review Body and were conducted within the provisions of the
Animals (Scientific Procedures) Act of 1986 (32), under project license
number 80/2533 and following the Laboratory Animal Science Associ-
ation Guiding Principles for Preparing for and Undertaking Aseptic
Surgery (33).
Male C57BL/6J mice (n = 40; 25.9 6 0.4 g), aged 6 wk, were
purchased from Charles River Laboratories (Margate, United Kingdom).
Mice were housed 4 per cage and under conditions of constant
temperature (21 6 2C) and humidity (55% 6 10%) and a standard
light-dark cycle (12 h/12 h) and were given food and water ad libitum
throughout. After a 2-wk acclimatization period of being fed a standard
RM3 diet (Rat and Mouse No. 3 Breeding Diet; Special Diets Services)
(34), which provided 11% of energy from fat, 27% from protein, and
62% from carbohydrates, mice (n = 8/group) were allocated to 1 of the 5
following feed pellet ½AQ8test diets for 10 wk: control (C), low-EPA-rich 9CO
(COL), high-EPA-rich CO (COH), low-EPA-rich FO (FOL), or high-
EPA-rich FO (FOH). The nutrient and FA compositions of the
experimental diets are given in Supplemental Tables 1–3.
Mice were weighed once a week, and food intake was recorded 3
times/wk. The diets were frozen in batches at 220C and defrosted and
replaced every other day to ensure minimal oxidation of the FAs. At the
end of the 10-wk intervention, food was removed for 16 h. The mice
were anesthetized by using 4% isoflurane in medical oxygen, and blood
was drawn by cardiac puncture into serum separation tubes (Becton
Dickinson). Glucose concentrations were measured in whole blood by
using an AlphaTRAK 2 glucose meter (Abbott Laboratories Ltd.). Blood
samples were then allowed to clot for 30 min at room temperature before
serum was separated by centrifugation (10 min, 1300 3 g, at room
temperature). Mice were transcardially perfused with an ice-cold saline
solution containing sodium heparin (10 U/mL). Livers were removed,
rinsed with ice-cold 150 mmol NaCl/L, blotted, and weighed. The right
lobes were stored in RNALater (Sigma-Aldrich) for gene expression
analysis. The remainder of liver, muscle (gastrocnemius), and brain
samples were snap-frozen, and all samples were stored at 280C for
further analysis. These tissues were chosen due to their central role in
EPA and DHA biosynthesis (liver), FA utilization (muscle), and high n–3
PUFA, and in particular DHA, content (brain).
Mouse diets. All diets were based on the TestDiet AIN-93M
semipurified diet 58M1 for rodents (TestDiet Europe; IPS Product
Supplies Ltd.) and provided 10% of energy from fat, 20% from protein,
and 70% from carbohydrates (Supplemental Tables 1 and 2 ½AQ10). The
control diet contained palm oil (PO; William Hodgson & Co.), which
was chosen as a high-saturated-fat oil source, typical of a Western-type
human diet. Furthermore, PO is low in ALA, thereby limiting endog-
enous EPA synthesis in the mouse tissue. Details of the metabolic
engineering, production, and composition of the transgenic EPA-rich CO
have been published previously (35, 36), with the oil providing 20%
EPA, 0% DHA, and 16%, 17%, and 66% of total SFAs, MUFAs, and
PUFAs, respectively ½AQ11.
The COL and COH diets contained 0.31% and 2.15% of transgenic
EPA-rich CO and the FOL and FOH diets contained 0.08% and 0.57%
of an EPA-rich FO (EPAX 6015 TG, EPA:DHA-4:1 ½AQ12; Epax A/S). The oil
content of all 4 diets contained up to 10% of energy with the use of PO ½AQ13.
This resulted in C, COL, COH, FOL, and FOH diets containing 0, 0.4,
3.4, 0.3, and 2.9 g EPA/kg diet, respectively.
9 Abbreviations used: AA, arachidonic acid; ALA, a-linolenic acid; C, control; CO,
Camelina oil; COH, high-EPA-rich Camelina oil; COL, low-EPA-rich Camelina oil;
Elovl, elongase; Fads, fatty acid desaturase; FO, fish oil; FOH, high-EPA-rich fish
oil; FOL, low-EPA-rich fish oil; HED, human equivalent dose; LA, linoleic acid; LC,
long-chain; Lxra, liver X receptor a; PO, palm oil; SDA, stearidonic acid; Srebp1c,
sterol regulatory element-binding protein 1c; TC, total cholesterol; TL, total lipid.
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These amounts of oils were chosen to provide human equivalent
doses (HEDs) of EPA of 500 mg/d (COL and FOL) and 3.5 g/d (COH
and FOH), which represent the minimal recommended EPA+DHA
intake (500 mg/d) and the 2- to 4-g/d dose, respectively, recommended by
the American Heart Association for TG lowering (12). The equivalent
mouse doses were determined on the basis of allometric scaling and body
surface area—based calculations considering the HED in a normal-weight
adult (70 kg) with the use of the following formula: HED (mg/kg) = AD½AQ14
(mg/kg) 3 [weight mouse (kg)/weight human (kg)](0.33) and assuming a
daily food intake of 5 g/d (37).
Lipid blood tests and FA analysis. Serum concentrations of total
cholesterol (TC), HDL cholesterol, and TGs in feed-deprived mice were
quantified with commercially available kits from Instrumentation
Laboratories on a clinical chemistry analyzer IL650 (Instrumentation
Laboratories). Total lipids (TLs) were extracted from 200 mg ground
diets, 150 mg liver, 200 mg brain, and 100 mg muscle samples by using
chloroform/methanol (2:1 vol:vol) containing 0.01% BHT as an
antioxidant. FAs were analyzed by GC-FID½AQ15 following the method
described previously (38).
RNA isolation and real-time qPCR. Total RNAwas isolated from the
livers of 6 mice per dietary treatment after being homogenized in 1 mL
TriReagent (Sigma-Aldrich), and cDNA was synthesized as detailed in
Betancor et al. (39). The expression of genes of interest (Supplemental
Table 4) was determined by qPCR, normalizing the results against
b-actin. qPCR was performed by using a Biometra TOptical Thermo-
cycler (Analytik Jena).
TG purification and positional analysis. The TG fraction from the
experimental oils was separated by thin layer chromatography½AQ16 as
previously described (40). FAME composition of these TG fractions was
obtained by heating the samples in methanol:toluene:H2SO4 (88:10:2,
by volume) (41). Positional analysis of purified TGs was performed
according to Ruiz-Lopez et al. (26).
Statistical analysis. Body weight, food intake, blood glucose, serum
lipids, and tissue FAs are presented as means 6 SEMs. The data were
checked for normality of distribution by using the Kolmogorov-Smirnoff
test and log-transformed when necessary. Homogeneity of variance was
established by using the Levene test. Statistical analyses of body weight
and food intake were performed by using 2-factor ANOVA with
repeated measures followed by Bonferronis multiple-comparison tests.
One-factor ANOVAwas used to test for the effects of diet on serum lipids
and tissue FA compositions, measured at 10 wk. Tukeys multiple-
comparison tests were used to establish intergroup differences when the
F value was significant. The statistical analysis was performed by using
the SPSS package (version 16.0; SPSS, Inc.), with P < 0.05 taken as being
significant. Gene expression results were analyzed by using the relative
expression software tool (REST ½AQ17) (42), which uses a pairwise fixed
reallocation randomization test (10,000 randomizations) with efficiency
correction.
Results
Body weight and food intake. There were no mouse deaths or
indications of ill health over the 10-wk intervention period, with
no impact of treatment on liver weight (Figure 1C). All of the
groups had a significant increase in body weight, ranging from
14% for the C group to 21–22% for the FOH and COH groups
(P = 0.002), with the change from baseline being significantly
higher in the COH and FOH groups relative to the C group
(Figure 1A). A significant difference in body weight (P < 0.005)
was observed between C and FOH groups from 6 wk onward,
which was associated with higher food consumption in the FOH
group compared with the C group (P < 0.001) (Figure 1B). A
higher body weight was also evident in the COH mice than in C
mice (P < 0.005) from week 8 onward, which was not reflected
in differences in food intake.
Diet analysis. Both EPA-rich CO diets (COL and COH) had a
higher content of linoleic acid (LA; 18:2n–6), total n–6 PUFAs,
and ALA than did the C or FOL and FOH diets (Supplemental
Table 3). These results are reflective of the presence of Camelina
sativa, a naturally C18-PUFA–rich oil.
The amounts of EPA were comparable in both the COL and
FOL (0.9% and 0.6%) and the COH and FOH (8.3% and
7.1%) diets, with 0.1% and 2.3% DHA present in the FOL and
FOH diets as a result of the inclusion of FO. The regiospecific
analysis of the TG fraction in the experimental oils showed that
almost all of the palmitic acid (16:0) and stearic acid (18:0) were
in the sn-2 position in the FO, compared with;20% in the CO.
FIGURE 1 Body weight (A), food consumption (B), and liver weight (C) in male C57BL/6J mice after 10 wk of feeding diets providing EPA as
EPA-rich transgenic Camelina oil or EPA-rich fish oil relative to a control diet. Values are means 6 SEMs, n = 8. *,#,xDifferences between groups
(P , 0.05, 2-factor ANOVA with repeated measures½AQ30 followed by Bonferronis multiple-comparison tests): *C compared with FOH, #C compared
with COH, xCOL compared with FOH. Week 10 data are not presented in panels A and B because mice had their food removed for 16 h before
killing, and therefore the data are not directly comparable to weeks 1–9. C, control diet; COH, EPA-rich Camelina oil, high dose; COL, EPA-rich
Camelina oil, low dose; FOH, EPA-rich fish oil, high dose; FOL, EPA-rich fish oil, low dose.
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Comparable proportions of EPA were present insn-2 in the FO
(46.0%) and CO (51.5%) (Supplemental Table 5).
Fasting glucose and blood lipids. Fasting blood glucose
concentrations were lower in the COH- and FOH-fed mice
relative to C mice (P = 0.01) (Figure 2A). No significant impact
of treatment on fasting serum TC, TGs, or HDL cholesterol was
observed (Figure 2B).
FA composition. The PUFA composition of the TLs in the liver
(Table 1) reflected, in general terms, the composition of the diets.
Significantly higher concentrations of EPAwere evident in all of
the experimental groups relative to the C group (P < 0.001), with
EPA enrichments in the following order: FOH = COH > COL >
FOL > C. DHA biosynthesis was evident in all of the groups,
with the concentrations of this FA 3–4 times higher in mice fed
the experimental diets compared with the C group (P < 0.001).
The liver TL total n–3 PUFA½AQ18 concentrations were in the
following order: COH = FOH > COL = FOL > C (P < 0.001).
The concentrations of LAwere higher in all of the experimental
groups compared with the C group (P < 0.000). Mice fed the C
diet showed higher concentrations of metabolites derived from
LA (20:2n–6, 20:3n–6, and 20:4n–6; 1.2%, 0.7%, and 8.2%,
respectively) when compared with FOH mice (0.1%, 0.3%, and
2.8%, respectively). SFA percentages were similar between
groups, with the exception of palmitic acid½AQ19 (P < 0.001).
In brain tissue (Table 2), the expected low concentrations of
EPA (0.2%) were observed, with no impact of diet. Relative to
all other groups, modestly higher DHA concentrations were
evident after the FOH intervention (P = 0.006), with associated
lower docosapentaenoic acid (22:5n–3) (except when compared
with FOL; P < 0.019) and arachidonic acid (AA½AQ20 ; 20:4n–6; P <
0.001). A significant impact of intervention on total n–3 PUFAs
(P = 0.004) and n–3 to n–6 PUFA ratio (P < 0.001) was also
evident. No significant impact of treatment on the SFA content
of brain tissue was observed.
Muscle EPA concentrations were <0.5%, with no impact of
diet on EPA or DHA content (Table 3). Total n–3 PUFAs were
not different between treatments, and the n–3 to n–6 ratio was
higher after the FOH diet (P = 0.037) than after the C diet. This
difference in the n–3 to n–6 ratio was the result of the low
concentration of total n–6 PUFAs observed in the FOH group (P
= 0.016), attributable to lower concentrations of LA metabolites
(20:2n–6, 20:3n–6, and 20:4n–6; P < 0.001). No significant
impact of treatment on muscle SFA content was observed.
FIGURE 2 Effects of 10 wk of feeding diets providing EPA as EPA-
rich transgenic Camelina oil or EPA-rich fish oil relative to a control diet
on serum glucose (A) and serum lipids (B) in male C57BL/6J mice.
Food was removed for 16 h before blood sample collection. Values are
means6 SEMs, n = 8. Labeled means without a common letter differ,
P , 0.05 (1-factor ANOVA followed by Tukeys multiple-comparison
tests). C, control diet; COH, EPA ½AQ31-rich Camelina oil, high dose; COL,
EPA-rich Camelina oil, low dose; FOH, EPA-rich fish oil, high dose;
FOL, EPA-rich fish oil, low dose; HDL-C, HDL cholesterol; TC, total
cholesterol.
TABLE 1 Main FAs ($ 0.5 g/100 g FAs) from liver total lipids of male C57BL/6J mice after 10 wk of
feeding diets providing EPA as EPA-rich transgenic Camelina oil or EPA-rich fish oil relative to a control
diet1
Diet, g/100 g FAs
FAs C COL COH FOL FOH P 2
14:0 0.5 6 0.0 0.5 6 0.1 0.6 6 0.0 0.5 6 0.1 0.6 6 0.1 NS
16:0 22.2 6 0.3d 23.6 6 0.5c,d 25.7 6 0.4a,b 24.3 6 0.3b,c 26.4 6 0.7a ,0.001
16:1n–7 6.4 6 0.4 6.2 6 0.5 5.1 6 0.4 5.5 6 0.6 6.0 6 0.5 NS
18:0 5.9 6 0.4 5.5 6 0.5 6.3 6 0.5 7.2 6 0.7 5.7 6 0.4 NS
18:13 43.9 6 1.4a 36.9 6 1.1b 26.6 6 0.8c 35.4 6 1.5b 33.2 6 0.7b ,0.001
18:2n–6 6.6 6 0.4d 9.2 6 0.4b,c 13.4 6 0.4a 7.8 6 0.3c,d 9.4 6 0.4b ,0.001
18:3n–3 0.0 6 0.0c 0.2 6 0.0b 1.2 6 0.1a 0.0 6 0.0c 0.1 6 0.0b ,0.001
20:1n–9 0.7 6 0.1a 0.2 6 0.1b 0.4 6 0.1a,b 0.2 6 0.1b 0.1 6 0.0b ,0.001
20:2n–6 1.2 6 0.1a 0.6 6 0.0c 0.3 6 0.0d 0.8 6 0.1b 0.1 6 0.0e ,0.001
20:3n–6 0.7 6 0.1a 0.7 6 0.1a 0.5 6 0.0a 0.8 6 0.1a 0.3 6 0.0b ,0.001
20:4n–6 8.2 6 0.7a 7.5 6 0.0a 6.4 6 0.5a 8.8 6 0.8a 2.8 6 0.2b ,0.001
20:5n–3 0.0 6 0.0d 0.4 6 0.0b 2.9 6 0.1a 0.2 6 0.0c 3.6 6 0.2a ,0.001
24:1 0.1 6 0.0c 0.4 6 0.0b 1.6 6 0.3a 0.3 6 0.0b 1.3 6 0.3a,b 0.001
22:6n–3 2.4 6 0.1b 7.2 6 0.8a 7.7 6 0.6a 7.2 6 0.6a 9.5 6 0.5a ,0.001
Total n–3 PUFAs 2.8 6 0.2c 8.0 6 0.8b 12.2 6 0.7a 7.7 6 0.6b 13.4 6 0.7a ,0.001
Total n–6 PUFAs 17.0 6 1.0b 18.3 6 0.9a,b 20.9 6 0.6a 18.5 6 0.9a,b 12.7 6 0.5c ,0.001
n–3 to n–6 PUFA ratio 0.2 6 0.0d 0.4 6 0.0c 0.6 6 0.0b 0.4 6 0.0c 1.0 6 0.0a ,0.001
1 Values are means 6 SEMs, n = 8. Totals include some minor components not shown. Labeled means in a row without a common letter
differ, P , 0.05. C, control; COH, EPA-rich Camelina oil, high dose; COL, EPA-rich Camelina oil, low dose; FOH, EPA-rich fish oil, high dose;
FOL, EPA-rich fish oil, low dose.
2 Derived by using 1-factor ANOVA followed by Tukeys multiple-comparison tests.
3 Contains n–9 and n–7 isomers.
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Gene expression. There were no significant differences in the
expression of Elovl2 and Elovl5 between treatments. Relative to
the C group, the expression of Fads1 was significantly lower in
the COH and FOH groups (P = 0.015), with COL and COH
feeding resulting in higher Fads2 expression (P = 0.045) (Figure
3A).
No significant impact of treatment on Lxra and Srebp1c gene
expression was observed (Figure 3B). A significant impact of diet
on Ppara (P = 0.04) and Pparg (P = 0.013) expression was
TABLE 2 Main FAs ($ 0.5 g/100 g FAs) from brain total lipids of male C57BL/6J mice after 10 wk of
feeding diets providing EPA as EPA-rich transgenic Camelina oil or EPA-rich fish oil relative to a control
diet1
Diet, g/100 g FAs
FAs C COL COH FOL FOH P 2
16:0 20.2 6 0.1 20.0 6 0.4 19.9 6 0.3 20.6 6 0.2 20.8 6 0.1 NS
16:1n–7 0.6 6 0.0 0.7 6 0.0 0.7 6 0.0 0.7 6 0.0 0.7 6 0.0 NS
18:0 20.8 6 0.2 20.1 6 0.6 20.6 6 0.2 20.8 6 0.2 21.0 6 0.2 NS
18:13 24.1 6 0.5 23.8 6 0.5 23.9 6 0.3 24.5 6 0.3 24.5 6 0.6 NS
18:2n–6 0.3 6 0.0b 0.5 6 0.0a 0.5 6 0.0a 0.5 6 0.0a 0.3 6 0.1a,b 0.043
18:4n–3 0.7 6 0.1 0.4 6 0.0 0.5 6 0.0 0.9 6 0.2 0.8 6 0.2 NS
20:1n–9 2.6 6 0.2a 1.9 6 0.3a 1.2 6 0.4a,b 0.5 6 0.0b 0.5 6 0.0b 0.002
20:3n–6 0.4 6 0.0b 0.5 6 0.0a 0.5 6 0.0a 0.5 6 0.0a 0.5 6 0.0a ,0.001
20:4n–6 9.7 6 0.1a 9.6 6 0.1a 8.9 6 0.2a 9.3 6 0.1a 7.2 6 0.2b ,0.001
20:4n–3 0.3 6 0.0 0.4 6 0.0 0.4 6 0.0 0.4 6 0.0 0.4 6 0.0 NS
20:5n–3 0.2 6 0.0 0.2 6 0.0 0.2 6 0.0 0.2 6 0.0 0.2 6 0.0 NS
22:5n–3 2.2 6 0.1a 2.2 6 0.0a 2.2 6 0.0a 2.2 6 0.2a,b 1.8 6 0.0b 0.019
24:1 0.1 6 0.0c 0.3 6 0.0b 0.7 6 0.0a 0.1 6 0.0b,c 0.8 6 0.0a ,0.001
22:6n–3 15.2 6 0.3b 16.8 6 0.6a,b 16.4 6 0.2a,b 16.4 6 0.2a,b 17.7 6 0.2a 0.006
Total n–3 PUFAs 18.7 6 0.2b 20.0 6 0.6a,b 19.7 6 0.2a,b 20.1 6 0.3a,b 20.8 6 0.2a 0.004
Total n–6 PUFAs 11.0 6 0.1a 11.0 6 0.2a 10.1 6 0.2b 10.8 6 0.1a,b 8.4 6 0.2c ,0.001
n–3 to n–6 PUFA ratio 1.7 6 0.0c 1.8 6 0.0b,c 2.0 6 0.0b 1.9 6 0.0b,c 2.5 6 0.1a ,0.001
1 Values are means 6 SEMs, n = 8. Totals include some minor components not shown. Labeled means in a row without a common letter
differ, P , 0.05. C, control; COH, EPA-rich Camelina oil, high dose; COL, EPA-rich Camelina oil, low dose; FOH, EPA-rich fish oil, high dose;
FOL, EPA-rich fish oil, low dose.
2 Derived by using 1-factor ANOVA followed by Tukeys multiple-comparison tests.
3 Contains n–9 and n–7 isomers.
TABLE 3 Main FAs ($ 0.5 g/100 g FAs) from muscle total lipids of male C57BL/6J mice after 10 wk of
feeding diets providing EPA as EPA-rich transgenic Camelina oil or EPA-rich fish oil relative to a control
diet1
Diet, g/100 g FAs
FAs C COL COH FOL FOH P 2
14:0 1.1 6 0.1b 1.2 6 0.0a,b 1.4 6 0.0a 1.3 6 0. 0a,b 1.4 6 0.0a 0.010
16:0 22.9 6 0.2 23.8 6 0.2 24.3 6 0.8 23.9 6 0.7 24.2 6 0.3 NS
16:1n–7 8.3 6 0.9 11.3 6 0.8 10.1 6 1.1 9.0 6 1.0 11.0 6 1.2 NS
18:0 6.4 6 0.6 5.3 6 0.4 5.6 6 0.8 6.6 6 1.1 4.1 6 0.5 NS
18:13 41.3 6 1.2a 36.7 6 1.3a,b 30.9 6 2.0b 38.6 6 2.8a,b 41.4 6 1.7a 0.017
18:2n–6 6.6 6 0.3 7.0 6 0.3 9.5 6 0.8 7.0 6 0.2 7.0 6 0.4 NS
20:1n–9 0.8 6 0.1 0.6 6 0.0 1.3 6 0.2 0.7 6 0.0 0.8 6 0.1 NS
20:2n–6 0.8 6 0.1a 0.4 6 0.0b 0.4 6 0.0b 0.5 6 0.1a,b,c 0.1 6 0.0c 0.002
20:3n–6 0.9 6 0.1a 0.8 6 0.1a 0.7 6 0.1a,b 0.7 6 0.1a,b 0.2 6 0.0b 0.013
20:4n–6 5.4 6 0.7a 4.6 6 0.4a 3.0 6 0.5a,b 4.1 6 0.7a 1.0 6 0.2b 0.002
22:1n–9 0.0 6 0.0b 0.1 6 0.0b 0.6 6 0.0a 0.1 6 0.0b 0.5 6 0.0a 0.000
24:1 0.4 6 0.0b 1.1 6 0.1a 3.0 6 0.5a 0.9 6 0.2a,b 1.6 6 0.3a,b 0.001
22:6n–3 4.0 6 1.4 6.3 6 0.8 6.5 6 1.2 5.7 6 1.2 6.0 6 1.0 NS
Total n–3 PUFAs 4.5 6 0.3 6.6 6 0.8 8.9 6 1.1 6.0 6 1.2 6.4 6 1.0 NS
Total n–6 PUFAs 14.0 6 1.0a 13.0 6 0.8a 13.7 6 0.4a 12.6 6 0.8a,b 8.4 6 0.3b 0.016
n–3 to n–6 PUFA ratio 0.3 6 0.0b 0.5 6 0.0a,b 0.7 6 0.1a,b 0.5 6 0.1a,b 0.8 6 0.1a 0.037
1 Values are means 6 SEMs, n = 8. Totals include some minor components not shown. Labeled means in a row without a common letter
differ, P , 0.05. C, control; COH, EPA-rich Camelina oil, high dose; COL, EPA-rich Camelina oil, low dose; FOH, EPA-rich fish oil, high dose;
FOL, EPA-rich fish oil, low dose.
2 Derived by using 1-factor ANOVA followed by Tukeys multiple-comparison tests.
3 Contains n–9 and n–7 isomers.
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observed, with higher expression for the COL compared with
the C diet for Ppara and the COH compared with the C diet for
Pparg.
Discussion
Although the impact of EPA and DHA on overall mortality and
the incidence and risk of a number of chronic diseases are well
recognized (43), the supply of EPA and DHA is limited, and
there is a great need to identify alternative and sustainable
sources of these beneficial FAs. Given the technological and
nutritional limitations associated with alternative sources under
investigation (microalgae, zooplankton, SDA-rich oils, etc.),
transgenic oilseed crops currently present the most effective
solution for the large-scale production of these n–3 LC-PU-
FAs (14). Here we show for the first time, to our knowledge, that
EPA-rich CO (20% total FAs as EPA), when used as a dietary
supplement in mice and providing doses physiologically relevant
to humans, is a bioavailable source of EPA, resulting in
comparable enrichment of EPA in the liver.
The oils were well tolerated, with no deaths during the study,
and the mice were in apparent good health. Previous studies in
C57BL/6J mice have shown that the inclusion of FO in the diet is
accompanied by weight loss (44, 45). However, in the present
study, higher EPA-rich CO and FO intakes (COH and FOH), as
part of a 10% of energy from fat diet, were associated with body
weight gain, and no differences were observed in liver weight.
These findings are more consistent with previous studies in
which FO was fed to mice (46, 47) and rats (48) as part of low-
fat regimes, which showed no major differences in body and
liver weight.
In the present study, and independent of oil source, n–3
LC-PUFA supplementation decreased fasting glucose concentra-
tions in a dose-dependent manner. These observations are in line
with previous rodent studies (49), but in humans FO supple-
mentation has not consistently affected glucose concentrations
(50–53). With regard to serum lipids, feeding mice CO and FO
did not modify TC, HDL-cholesterol, or TG concentrations. The
TG-lowering effect of FOs in both normolipidemic and hyper-
triglyceridemic individuals is well documented (54, 55). Never-
theless, similar to our results, no differences in plasma TGs or
TC have been reported previously in mice fed low doses of FO as
part of low-fat treatments (56). Significant differences in
lipoprotein profiles and metabolism between rodents and
humans are likely to explain, in large part, the interspecies
differences in responsiveness of serum lipids to EPA and DHA
supplementation.
The effect of regiospecificity of dietary TG bioavailability has
been previously studied (29, 30), indicating a preferential
absorption of FAs when present at the TG sn-2 position.
Moreover, FO functional characteristics seem to be related to the
positional distribution of EPA and DHA on TGs (29, 57). For
example, in a recent study in C57BL/6J mice by Yoshinaga et al.
(29), DHA in the sn-2 position was associated with greater liver
DHA accumulation and serum and liver TG lowering, whereas
EPA in the sn-1 and -3 positions had a greater impact on
lowering hepatic cholesterol concentrations. In the present
study, regiospecific analysis showed similar proportions of EPA
in the sn-2 position of TGs in the CO and FO. This is consistent
with the uniform response of serum lipids and tissue EPA
concentrations reported in mice fed the FO- and CO-based diets.
Our results showed that the EPA-rich CO was as efficient as
FO at enriching liver EPA in a dose-dependent manner. Many
rodent studies reported increases in hepatic EPA and DHA after
FO supplementation, with the enrichment being variable and
dependent on the EPA+DHA dose, the EPA to DHA ratio, and
the overall composition of the diets (48, 58, 59). Increases in
EPA, observed after COH and FOH feeding, were comparable
FIGURE 3 Expression measured by qPCR of long-chain PUFA biosynthesis pathway genes (A) and transcription factor genes (B) in livers of
male C57BL/6J mice after 10 wk of feeding diets providing EPA as EPA-rich transgenic Camelina oil or EPA-rich fish oil relative to a control diet.
Values are normalized expression ratios (means 6 SEMs; n = 6) of the expression of genes in mice fed the experimental diets relative to the
control diet. Statistical differences were determined by a randomization test (REST½AQ32 ). Labeled means without a common letter differ, P , 0.05. C,
control diet; COH, EPA-rich Camelina oil, high dose; COL, EPA-rich Camelina oil, low dose; Elovl2, elongation of ve½AQ33 ry-long-chain FA 2; Elovl5,
elongation of very-long-chain FA 5; Fads1, FA desaturase 1; Fads2, FA desaturase 2; FOH, EPA-rich fish oil, high dose; FOL, EPA-rich fish oil, low
dose; Lxra, liver X receptor a; Ppara, peroxisome proliferator–activated receptor a; Pparg, peroxisome proliferator–activated receptor g; Srebp1c,
sterol regulatory element-binding protein 1c.
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to those reported for the phospholipid fraction of liver from
mice fed an FO providing comparable EPA intakes (59).
Previously, dietary EPA, although signiÞcantly elevating
hepatic and circulating EPA in mice, had only modest effects
on DHA accumulation (60). Consistent with these results, the
Japanese EPA intervention study (JELIS½AQ21 ) showed that feeding
1.8 g EPA/d had little impact on plasma DHA concentrations in
humans (61). In the present study, CO and FO feeding translated
into comparable concentrations of liver DHA, with no dose-
response evident, showing de novo synthesis in mice that
received little (FOL) or no (COL, COH) DHA. The accumula-
tion of DHA in mice fed the EPA-CO can be explained by the
high amounts of ALA present in the COL and COH diets, which
is characteristic of the CO, and the higher Fads2 expression
observed in the CO groups. This enzyme is responsible for the
first and last desaturation steps required to synthesize DHA from
ALA (62), and its expression has been shown to be upregulated
in the livers of n–3 PUFA–deprived rats½AQ22 (63) and downregulated
after feeding n–3 LC-PUFAs (31).
Feeding EPA and DHA in both rodent and human studies
resulted in a marked increase in n–3 LC-PUFAs in tissues at the
expense of n–6 FAs (64). Similar to previous studies (60), we also
observed that dietary DHA, more than EPA, lowered hepatic AA
content, which may be partly due to the downregulation of
Fads1 expression observed, which is involved in AA synthesis
from LA. Because elongases are also essential in the biosynthesis
of LC-PUFAs, we analyzed the effect of CO and FO on the
hepatic expression of Elovl2 and Elovl5, and no impact of
treatment on their expression was evident. Previously, feeding
FO had no effect on Elovl2 mRNA abundance, but a down-
regulation on Elovl5 mRNA levels has been observed (65, 66).
At the transcription level, both desaturases are regulated by
the transcription factors Ppara and Srebp1½AQ23 (67). Ppara is a
ligand-activated transcriptional factor central to lipid homeo-
stasis and which is influenced by FA status (31, 65, 66). Previous
studies have shown that Ppara activation is increased by n–3 and
n–6 PUFAs (68), and this activation led to increased expression
of FA oxidation genes, which resulted in decreased hepatic and
plasma TGs (69). In the present study, consistent with these
observations, there was a general trend toward increased Ppara
and Pparg after CO and FO feeding, with the etiologic basis of
the greatest expression after COL currently unknown.
Srebp1c is a major transcriptional factor that regulates
enzymes involved in FA and TG synthesis (67). Liver Srebp1c
expression has been shown to be downregulated in C57BL/6J
mice fed FO as part of both high-fat (70) and low-fat (67)
regimes. The present results showed no changes in hepatic
Srebp1c mRNA levels after EPA administration, which was
consistent with some previous research in which mRNA
expression levels of Srebp1c in mice remained unchanged after
EPA ethyl ester treatment, although changes in Srebp1c mature
protein concentrations were evident (64). Lxr½AQ24 represents a
further molecular target of dietary PUFAs, which regulates
lipogenic gene expression either directly or via regulation of
transcription of the Srebp1c gene (71). In the present study, no
significant differences were found in Lxr, which could explain, at
least in part, the lack of impact of intervention on Srebp1c.
No impact of treatment on brain EPA concentrations was
observed, with EPA constituting 0.2% of the FA pool across all
groups. This finding is consistent with previous observations, in
which, despite comparable potential for transfer across the
blood-brain barrier to DHA, EPA represented only a minor
component of brain membranes, with supplementation failing to
result in EPA enrichment (72). Although some increases in brain
DHA were observed, total n–3 PUFAs and the n–3 to n–6 ratio
were similar between treatments and less pronounced than in
liver.
In contrast to the liver, skeletal muscle EPA concentrations
were constitutively low and supplementation with CO and FO
had no significant effect on n–3 LC-PUFAs or total n–3
concentrations. Several studies have corroborated that the
accumulation of n–3 PUFAs is tissue-dependent (62). The
skeletal muscle is mainly involved in lipid oxidation to produce
chemical energy. This may explain why DHA is the only n–3
PUFA that accumulates in this tissue given that it has the longest
acyl chain length and the highest degree of unsaturation, which
can lead to steroisomeric-induced resistance to b-oxidation (73).
In conclusion, EPA from oil derived from genetically mod-
ified Camelina had comparable effects on liver EPA status,
relative to equivalent doses derived from FO. These data could
help support any future licensing of this EPA-rich CO for
consumption in randomized controlled trials to allow its
establishment as a bioavailable and efficacious alternative
sustainable source of EPA in humans.
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